Periprocedural myocardial injury and myocardial infarction (MI) are not infrequent
complications of percutaneous coronary intervention (PCI) and are associated with greater …

Insights into the genetic basis of human disease are helping to address some of the key
challenges in new drug development including the very high rates of failure. Here we review …

Background Atherosclerosis is recognized as a systemic low‐grade inflammatory disease.
Furthermore, the dysregulation of the inflammatory response and its timely resolution is a …

Summary Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-
6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and …

Background: Aging is associated with a chronic low-grade inflammatory state. This condition
may affect the acute inflammatory response involved in ST-segment–elevation myocardial …

Abstract Purpose of Review Inflammation plays a key role in clearing cellular debris and
recovery after acute myocardial infarction (AMI). Dysregulation of or prolonged inflammation …

Highlights•IL-19 is a promising biomarker in atherosclerosis, and reduces atherosclerosis
development.•Several drugs have been investigated in clinical trials as anti-inflammatory …

Aims Little is known about the clinical relevance of interleukin (IL)-6 in patients with acute ST-
elevation myocardial infarction (STEMI). This study examined the possible associations of …

Coronary atherosclerotic heart disease is a serious threat to human health. The results of the
Canakinumab Anti-Inflammatory Thrombosis Outcome Study published in 2017 put an end …

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and
mortality worldwide. Even with excellent control of low-density lipoprotein cholesterol (LDL …